To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type abstract
PMID
Authors Y. Honma, I. Kinoshita, C. Ishioka, K. Ishigaki, T. Enokida, H. Hayashi, S. Nishiwaki, N. Nishida, M. Muto, M. Tabata, M. Ito, R. Ko, K. Sunami, T. Shimoi, N. Yamamoto
Title 621P Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Journal Vol Issue Date Pages Journal Short Title
Annals of Oncology 35 Supplement 2 September 2024
URL https://www.annalsofoncology.org/article/S0923-7534(24)02207-5/fulltext
Abstract Text Background BRAF gene alterations, representing BRAF V600E mutation, are prevalent in melanoma, thyroid cancer, non-small cell lung cancer, and other malignancies to a lesser degree. The BELIEVE trial is a single-arm, open-label Japanese multi-institutional study equivalent to the NCI-MATCH trial, and we report the results of the cohort that assessed the efficacy of E+B in BRAF-altered solid tumors refractory to standard of care. Methods Pts with solid tumors recommended E+B in molecular tumor board based on comprehensive genomic profiling were eligible. Participants received Encorafenib 450 mg once daily and Binimetinib 45 mg twice daily continuously until disease progression or intolerable toxicity occurred. The primary endpoint was the investigator-assessed objective response rate (ORR) according to the RECIST v1.1. The clinical hypothesis was that patients would respond to the genotype-matched drugs. Bayesian analysis using a prior distribution with an expected ORR of 30% [Beta (0.6, 1.4)] was carried out. Results Forty-nine pts were extracted as a full analysis set with a median age of 65. The primary site of 23 pts was thyroid, central nervous system in 6, and biliary tract in 4. BRAF V600E mutation was detected in 43 pts, other BRAF mutation in 5, and BRAF fusion in 1, respectively. The confirmed ORR was 32.7% (95% CI, 20.0-47.5), which showed expected efficacy. Median PFS and PFS rate at 6 months were 4.8 months (95% CI, 2.2-6.9) and 37.5%. Data regarding overall survival was premature, with a median of 11.7 months at the time of analysis. Furthermore, the median PFS was 2.1 months (95% CI, 0.6 to 10.9 months) for the eight patients without target lesions in the exploratory analysis. Frequently observed adverse events (AEs) in a safety analysis set (58 pts) were ALT increased (8.6%), nausea (6.9%), anemia (6.9%), creatinine increased (6.9%), and CPK increased (6.9%). Grade ≥3 AEs was observed in 34.5%. Conclusions This study showed the efficacy of matched drubs with an ORR of 32.7%, and other clinical outcomes also encouraged the efficacy of E+B in BRAF-altered solid tumors.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF V600E Advanced Solid Tumor predicted - sensitive Binimetinib + Encorafenib Phase II Actionable In a Phase II trial (BELIEVE), treatment with the combination of Braftovi (encorafenib) and Mektovi (binimetinib) resulted in an objective response rate of 32.7%, median progression-free survival (PFS) of 4.8 months, and 6-month PFS rate of 37.5% in patients with advanced solid tumors harboring BRAF V600E (n=43), other BRAF mutation (n=5), or a BRAF fusion (n=1) (Ann Oncol (2024) 35 (Suppl_2): S497). detail...